Plectasin

Plectasin is an antibiotic protein from the mushroom Pseudoplectania nigrella. It was initially discovered in 2005[1] and commercialised by Novozymes.[2] Plectasin belongs to the antimicrobial peptide class called fungal defensins, which is also present in invertebrates such as flies and mussels.

Clinical trials

Pre-clinical tests in mice have shown promising results in that multiresistant bacteria have problems mutating resistance against plectasin,[3] which acts by directly binding the bacterial cell-wall precursor Lipid II.[4]

At the end of 2008, Novozymes signed a global licensing agreement with Sanofi-Aventis for the further development and marketing of NZ2114, a derivative of plectasin, as a treatment for gram-positive bacterial infections, e.g. Streptococcus and Staphylococcus which are resistant to all existing antibiotics.[2][5]

References
  1. Mygind, Per H.; Fischer, Rikke L.; Schnorr, Kirk M.; Hansen, Mogens T.; Sönksen, Carsten P.; Ludvigsen, Svend; Raventós, Dorotea; Buskov, Steen; Christensen, Bjarke; De Maria, Leonardo; Taboureau, Olivier (2005). "Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus". Nature. 437 (7061): 975–980. doi:10.1038/nature04051. ISSN 1476-4687. PMID 16222292. S2CID 4423851.
  2. "Novozymes reveals knowledge on new antibiotic against resistant bacteria". Novozymes. 2010-05-28. Retrieved 2010-05-28.
  3. "Plectasin NZ2114 - Novel Microbial Agent". Drug Development Technology. Retrieved 2010-05-28.
  4. Kristensen, HH; et al. (2010). "Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II". Science. 328 (5982): 1168–1172. doi:10.1126/science.1185723. hdl:1874/202594. PMID 20508130. S2CID 206524928.
  5. Kristensen, HH; et al. (2009). "In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model". Antimicrob. Agents Chemother. 53 (7): 3003–3009. doi:10.1128/AAC.01584-08. PMC 2704636. PMID 19414576.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.